| BE0027-25MG
| InVivoMab anti-mouse CD106 (VCAM-1)
| 25 mg
| BioXCell
| in vivoVCAM-1 neutralization, Immunofluorescence
|
| Rat
| Mouse
| Consultar
|
| BE0032-100MG
| InVivoMab anti-mouse CTLA-4 (CD152)
| 100 mg
| BioXCell
| in vivo CTLA-4 neutralization, in vitro CTLA-4 neu
|
| Armenian hamster
| Mouse
| Consultar
|
| BE0058-50MG
| InVivoMab anti-mouse TNF?
| 50 mg
| BioXCell
| in vivo TNF? neutralization, in vitro TNF? neutral
|
| Rat
| Mouse
| Consultar
|
| BE0075-25MG
| InVivoMab anti-mouse Ly6G/Ly6C (Gr-1)
| 25 mg
| BioXCell
| in vivo depletion of Gr-1+ myeloid cells, Flow cyt
|
| Rat
| Mouse
| Consultar
|
| BE0020-2-25MG
| InVivoMab anti-human CD54 (ICAM-1)
| 25 mg
| BioXCell
| in vitro T cell stimulation/activation, Immunofluo
|
| Mouse
| Human
| Consultar
|
| BE0004-2-5MG
| InVivoMab anti-human CD8?
| 5 mg
| BioXCell
| in vivo CD8+ T cell depletion in humanized mice
|
| Mouse
| Human
| Consultar
|
| BE0033-1-25MG
| InVivoMab anti-mouse OX40L (CD134L)
| 25 mg
| BioXCell
| in vivo blocking of OX40/OX40L signaling, in vitro
|
| Rat
| Mouse
| Consultar
|
| BE0039-25MG
| InVivoMab anti-mouse/human CD44
| 25 mg
| BioXCell
| in vivo CD44 neutralization
|
| Rat
| mouse/huma
| Consultar
|
| BE0045-50MG
| InVivoMab anti-mouse IL-4
| 50 mg
| BioXCell
| in vitro IL-4 neutralization, in vivo IL-4 neutral
|
| Rat
| Mouse
| Consultar
|
| BE0019-1-100MG
| InVivoMab anti-human CD47
| 100 mg
| BioXCell
| in vitro CD47 neutralization, iin vivo CD47 neutra
|
| Mouse
| Human
| Consultar
|
| BE0047-5MG
| InVivoMab anti-mouse IL-6R
| 5 mg
| BioXCell
| in vivo blocking of IL-6/IL-6R signaling, in vitro
|
| Rat
| Mouse
| Consultar
|
| BE0072-25MG
| InVivoMab anti-mouse T15 VH and T15 VL regions of IgM
| 25 mg
| BioXCell
| ELISA
|
| Mouse
| Mouse
| Consultar
|
| BE0060-25MG
| InVivoMab anti-mouse VEGFR-2
| 25 mg
| BioXCell
| in vivo blocking of VEGF/VEGFR-2 signaling, in vit
|
| Rat
| Mouse
| Consultar
|
| BE0031-1MG
| InVivoMab anti-mouse OX40 (CD134)
| 1 mg
| BioXCell
| in vivo OX40 activation, in vitro OX40 activation
|
| Rat
| Mouse
| Consultar
|
| BE0062-5MG
| InVivoMab anti-mouse/human Integrin ?7
| 5 mg
| BioXCell
| Immunoprecipitation, Western blot, Flow cytometry
|
| Rat
| mouse/huma
| Consultar
|
| BE0021-25MG
| InVivoMab anti-mouse L-Selectin (CD62L)
| 25 mg
| BioXCell
| In vivo CD62L neutralization
|
| Rat
| Mouse
| Consultar
|
| BE0020-1-100MG
| InVivoMab anti-mouse CD54 (ICAM-1)
| 100 mg
| BioXCell
| In vivo ICAM-1 neutralization
|
| Rat
| Mouse
| Consultar
|
| BE0071-100MG
| InVivoMab anti-mouse/human VLA-4 (CD49d)
| 100 mg
| BioXCell
| in vivo VLA-4 neutralization, in vitro VLA-4 neutr
|
| Rat
| mouse/huma
| Consultar
|
| BE0035-5MG
| InVivoMab anti-mouse MAdCAM-1
| 5 mg
| BioXCell
| in vivo MAdCAM-1 neutralization, Immunofluorescenc
|
| Rat
| Mouse
| Consultar
|
| BE0034-25MG
| InVivoMab anti-mouse LPAM-1 (Integrin ?4?7)
| 25 mg
| BioXCell
| in vivo Integrin ?4?7 neutralization, Flow cytomet
|
| Rat
| Mouse
| Consultar
|
| BE0007-1MG
| InVivoMab anti-mouse/human CD11b
| 1 mg
| BioXCell
| in vivo CD11b neutralization, ILC2 cell purificati
|
| Rat
| mouse/huma
| Consultar
|
| BE0016-2-5MG
| InVivoMab anti-mouse CD40
| 5 mg
| BioXCell
| in vivo CD40 activation, in vitro B cell stimulati
|
| Rat
| Mouse
| Consultar
|
| BE0019-5MG
| InVivoMab anti-mouse CD45RB
| 5 mg
| BioXCell
| in vivo anti-CD45RB–mediated tolerance induction,
|
| Rat
| Mouse
| Consultar
|
| BE0017-1-1MG
| InVivoMab anti-mouse CD154 (CD40L)
| 1 mg
| BioXCell
| in vivo blocking of CD40/CD40L signaling, in vitro
|
| Armenian hamster
| Mouse
| Consultar
|
| BE0021-50MG
| InVivoMab anti-mouse L-Selectin (CD62L)
| 50 mg
| BioXCell
| In vivo CD62L neutralization
|
| Rat
| Mouse
| Consultar
|
| BE0025-1MG
| InVivoMab anti-mouse CD86 (B7-2)
| 1 mg
| BioXCell
| In vivo CD86 blockade, Flow cytometry
|
| Rat
| Mouse
| Consultar
|
| BE0014-5MG
| InVivoMab anti-human CD25 (IL-2R?)
| 5 mg
| BioXCell
| Immunoprecipitation, Immunofluorescence
|
| Mouse
| Human
| Consultar
|
| BE0020-2-100MG
| InVivoMab anti-human CD54 (ICAM-1)
| 100 mg
| BioXCell
| in vitro T cell stimulation/activation, Immunofluo
|
| Mouse
| Human
| Consultar
|
| BE0024-50MG
| InVivoMab anti-mouse CD80 (B7-1)
| 50 mg
| BioXCell
| In vivo CD80 blockade, Flow cytometry
|
| Armenian hamster
| Mouse
| Consultar
|
| BE0057-50MG
| InVivoMab anti-mouse/human/rat/monkey/hamster/canine/bovine TGF-?
| 50 mg
| BioXCell
| in vivo TGF? neutralization, in vitro TGF? neutral
|
| Mouse
| mouse/human/rat/monkey/hamster/canine/bovin
| Consultar
|
| BE0020-2-5MG
| InVivoMab anti-human CD54 (ICAM-1)
| 5 mg
| BioXCell
| in vitro T cell stimulation/activation, Immunofluo
|
| Mouse
| Human
| Consultar
|
| BE0012-50MG
| InVivoMab anti-mouse CD25 (IL-2R?)
| 50 mg
| BioXCell
| in vivo regulatory T cell depletion, Flow cytometr
|
| Rat
| Mouse
| Consultar
|
| BE0001-1FAB 25MG
| InVivoMab anti-mouse CD3? F(ab')2 fragment
| 25 mg
| BioXCell
| in vivo T cell depletion
|
| Hamster
| Mouse
| Consultar
|
| BE0021-1MG
| InVivoMab anti-mouse L-Selectin (CD62L)
| 1 mg
| BioXCell
| In vivo CD62L neutralization
|
| Rat
| Mouse
| Consultar
|
| BE0054-100MG
| InVivoMab anti-mouse IFN?
| 100 mg
| BioXCell
| in vivo IFN? neutralization, in vitro IFN? neutral
|
| Rat
| Mouse
| Consultar
|
| BE0019-50MG
| InVivoMab anti-mouse CD45RB
| 50 mg
| BioXCell
| in vivo anti-CD45RB–mediated tolerance induction,
|
| Rat
| Mouse
| Consultar
|
| BE0054-5MG
| InVivoMab anti-mouse IFN?
| 5 mg
| BioXCell
| in vivo IFN? neutralization, in vitro IFN? neutral
|
| Rat
| Mouse
| Consultar
|
| BE0075-1-100MG
| InVivoMab anti-mouse Ly6G
| 100 mg
| BioXCell
| in vivo neutrophil depletion, in vivo MDSC depleti
|
| Rat
| Mouse
| Consultar
|
| BE0001-1-25MG
| InVivoMab anti-mouse CD3?
| 25 mg
| BioXCell
| in vivo T cell depletion, in vitro T cell stimulat
|
| Armenian hamster
| Mouse
| Consultar
|
| BE0005-1-100MG
| InVivoMab anti-mouse LFA-1? (CD11a)
| 100 mg
| BioXCell
| in vivo LFA-1 neutralization
|
| Rat
| Mouse
| Consultar
|
| BE0011-100MG
| InVivoMab anti-mouse CD22
| 100 mg
| BioXCell
| in vivo B cell depletion in combination with anti-
|
| Mouse
| Mouse
| Consultar
|
| BE0014-25MG
| InVivoMab anti-human CD25 (IL-2R?)
| 25 mg
| BioXCell
| Immunoprecipitation, Immunofluorescence
|
| Mouse
| Human
| Consultar
|
| BE0067-5MG
| InVivoMab anti-mouse B220
| 5 mg
| BioXCell
| in vivo B cell depletion, in vitro B cell negative
|
| Rat
| Mouse
| Consultar
|
| BE0051-50MG
| InVivoMab anti-mouse IL-12 p40
| 50 mg
| BioXCell
| in vivo IL-12p40 neutralization, p40 affinity chr
|
| Rat
| Mouse
| Consultar
|
| BE0029-50MG
| InVivoMab anti-mouse IFN?R (CD119)
| 50 mg
| BioXCell
| in vivo IFN?R neutralization
|
| Rat
| Mouse
| Consultar
|
| BE0015-5-1MG
| InVivoMab anti-mouse CD28
| 1 mg
| BioXCell
| in vitro T cell stimulation/activation
|
| Armenian hamster
| Mouse
| Consultar
|
| BE0087-100MG
| InVivoMab polyclonal Syrian hamster IgG
| 100 mg
| BioXCell
|
|
| Syrian hamster
| n/
| Consultar
|
| BE0040-25MG
| InVivoMab anti-rat CD28
| 25 mg
| BioXCell
| in vitro T cell stimulation/activation, Flow cytom
|
| Mouse
| Rat
| Consultar
|
| BE0003-2-100MG
| InVivoMab anti-human CD4
| 100 mg
| BioXCell
| in vitro T cell stimulation/activation, in vivo CD
|
| Mouse
| Human
| Consultar
|
| BE0049-100MG
| InVivoMab anti-mouse IL-10
| 100 mg
| BioXCell
| in vivo IL-10 neutralization, in vitro IL-10 neutr
|
| Rat
| Mouse
| Consultar
|
